Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from VistaGen Therapeutics ( (VTGN) ).
Vistagen Therapeutics (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company focused on neuroscience, leveraging nose-to-brain neurocircuitry to develop intranasal product candidates known as pherines. Its pipeline includes fasedienol in U.S. Phase 3 trials for social anxiety disorder, itruvone for major depressive disorder, and refisolone for menopausal vasomotor symptoms, targeting rapid-onset, potentially safer alternatives to traditional pharmacologic treatments.
On May 18, 2026, Vistagen appointed Angel S. Angelov, M.D., MBA, as Chief Medical Officer, underscoring its drive to advance multiple neuropsychiatric and women’s health programs. Angelov, a board-certified psychiatrist with over two decades of clinical development and medical affairs experience at companies including Theranica, Karuna Therapeutics, Neurocrine Biosciences, Novartis and Teva, will receive a $425,000 base salary, signing bonus and stock options for 150,000 shares, aligning his incentives with shareholders and reinforcing Vistagen’s leadership bench as it pushes its pherine candidates through late-stage development.
The most recent analyst rating on (VTGN) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.
Spark’s Take on VTGN Stock
According to Spark, TipRanks’ AI Analyst, VTGN is a Neutral.
The score is held down primarily by weak financial performance (large losses and significant ongoing cash burn on very small revenue) and longer-term bearish technical positioning (well below 100/200-day averages). Partially offsetting this are a low-leverage balance sheet and cautiously neutral clinical/program updates from the earnings call, while corporate events add both upside (refisolone U.S. Phase 2 clearance) and meaningful listing/governance overhangs (Nasdaq compliance issues).
To see Spark’s full report on VTGN stock, click here.
More about VistaGen Therapeutics
Vistagen Therapeutics (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company focused on neuroscience, leveraging nose-to-brain neurocircuitry to develop intranasal product candidates known as pherines. Its pipeline includes fasedienol in U.S. Phase 3 trials for social anxiety disorder, itruvone for major depressive disorder, and refisolone for menopausal vasomotor symptoms, targeting rapid-onset, potentially safer alternatives to traditional pharmacologic treatments.
On May 18, 2026, Vistagen appointed Angel S. Angelov, M.D., MBA, as Chief Medical Officer, underscoring its drive to advance multiple neuropsychiatric and women’s health programs. Angelov, a board-certified psychiatrist with over two decades of clinical development and medical affairs experience at companies including Theranica, Karuna Therapeutics, Neurocrine Biosciences, Novartis and Teva, will receive a $425,000 base salary, signing bonus and stock options for 150,000 shares, aligning his incentives with shareholders and reinforcing Vistagen’s leadership bench as it pushes its pherine candidates through late-stage development.
Average Trading Volume: 762,555
Technical Sentiment Signal: Sell
Current Market Cap: $24.76M
See more insights into VTGN stock on TipRanks’ Stock Analysis page.